What Is the Half-Life of Retatrutide?

The half-life of retatrutide is approximately seven days, based on pharmacokinetic data reported in clinical trials. This figure explains why retatrutide was administered as a once-weekly subcutaneous injection in those studies. Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP and glucagon receptors, and it currently holds no marketing authorisation in the UK or elsewhere. All information presented here is drawn from named clinical trial publications and is intended to inform, not to guide personal treatment decisions. Anyone seeking licensed weight-management options should speak with their GP.

What is the half-life of retatrutide and what does it mean?

Retatrutide has an estimated half-life of approximately seven days, supporting once-weekly dosing in trials. This means stable drug levels throughout the week, but also a prolonged period of activity if a dose is missed or a side effect occurs.

Retatrutide has an estimated half-life of approximately seven days, which is why it was administered as a once-weekly subcutaneous injection in clinical trials.^[1][2] A drug's half-life is the time taken for its concentration in the blood to fall by half; a longer half-life generally allows for less frequent dosing and more stable drug levels between doses. For retatrutide, the seven-day half-life aligns it with other long-acting agents in the same class, such as semaglutide and tirzepatide, which are also given weekly.

It is important to note that retatrutide holds no marketing authorisation in the UK or anywhere else. It is an investigational medicine available only within authorised clinical trials. The pharmacokinetic data described here, including the half-life figure, come from findings reported in named clinical trial publications and should be understood in that context. No practical dosing or administration guidance is provided here, as doing so would be inappropriate for an unlicensed medicine outside a trial setting.

The clinical relevance of a seven-day half-life is that drug levels remain relatively consistent throughout the week, potentially reducing peaks and troughs that can be associated with side effects or variable efficacy. However, it also means that if a dose is missed or a side effect occurs, the drug remains active in the body for a prolonged period. Anyone participating in a retatrutide trial who has concerns about their dosing schedule should raise these directly with their trial team.

How does retatrutide work in the body?

Retatrutide simultaneously activates GLP-1, GIP and glucagon receptors, distinguishing it from semaglutide (GLP-1 only) and tirzepatide (GLP-1 and GIP). Glucagon receptor agonism is thought to increase energy expenditure and promote fat breakdown alongside the appetite-reducing effects of GLP-1.

Retatrutide is a triple receptor agonist that simultaneously activates three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors.^[2][6] This triple mechanism distinguishes it from currently authorised medicines: semaglutide (Wegovy, Ozempic) acts on GLP-1 receptors alone, while tirzepatide (Mounjaro) acts on both GLP-1 and GIP receptors.^[20][21] The addition of glucagon receptor agonism is thought to increase energy expenditure and promote fat breakdown (lipolysis), which may contribute to the metabolic effects observed in trials.^[7][8]

GLP-1 receptor agonism reduces appetite, slows gastric emptying and stimulates insulin secretion in a glucose-dependent manner, meaning insulin release is tied to blood glucose levels rather than occurring unconditionally.^[9][10] GIP receptor agonism is believed to complement GLP-1 activity and may also influence fat tissue directly. Glucagon receptor agonism, by contrast, raises blood glucose in isolation, but when combined with GLP-1 activity, the net effect on glucose appears to be modulated, while the energy-expenditure and fat-mobilising properties of glucagon are retained.

Because retatrutide is still investigational, the full picture of how these three mechanisms interact in humans over the long term is not yet established. The pharmacological rationale is based on preclinical data and the findings of early-phase trials. Researchers continue to study how the balance of receptor activity translates into clinical outcomes across different patient populations, including those with type 2 diabetes and those with obesity without diabetes.

What has clinical trial research reported about retatrutide so far?

Phase 2 data published in the New England Journal of Medicine (2023) reported substantial mean body weight reductions at the highest dose over 48 weeks. Phase 3 trials (TRIUMPH and TRANSCEND programmes) are underway or reporting initial results, but positive findings do not equate to regulatory approval.

Phase 2 trial data for retatrutide in adults with obesity were published in the New England Journal of Medicine in 2023, reporting findings from a randomised, double-blind, placebo-controlled study.^[2][6] In that trial, participants receiving the highest dose of retatrutide over 48 weeks experienced substantial mean reductions in body weight compared with placebo.^[2][6] Separately, Phase 2 data in adults with type 2 diabetes have also been reported, showing reductions in both body weight and glycated haemoglobin (HbA1c).^[14][15] These are trial findings in specific populations over defined durations and cannot be generalised as predictions of what any individual would experience.

The Phase 3 programme, known as TRIUMPH (which includes TRIUMPH-1 to TRIUMPH-4) and TRANSCEND (including TRANSCEND-T2D-1, published in The Lancet), is now underway or has reported initial results.^[3][16] These larger, longer trials are designed to provide more robust evidence on efficacy and safety across broader populations, including people with type 2 diabetes and cardiovascular risk factors. The TRANSCEND-T2D-1 data represent a significant step in the evidence base beyond the earlier Phase 2 findings.

It is essential to understand that positive trial findings do not equate to regulatory approval. Retatrutide has not been authorised by the MHRA, and no timeline for a UK marketing authorisation application can be given. The medicine can be prescribed or supplied only within an authorised clinical trial. Anyone interested in licensed weight-management treatments should speak with their GP, who can discuss currently available options.

What are the known and suspected side effects of retatrutide?

Gastrointestinal effects including nausea, vomiting, diarrhoea and constipation are the most commonly reported adverse events in retatrutide trials, generally mild to moderate. Modest heart rate increases have also been reported, consistent with the broader GLP-1 receptor agonist class.

The side effects reported in retatrutide clinical trials are broadly consistent with those seen across the GLP-1 receptor agonist class, with gastrointestinal effects being the most commonly reported. In the Phase 2 obesity trial, nausea, vomiting, diarrhoea and constipation were among the most frequently noted adverse events, and these were generally more common at higher doses.^[2][6] Most gastrointestinal effects were described as mild to moderate in severity and tended to occur during dose escalation phases.

Because retatrutide also activates glucagon receptors, there is theoretical interest in whether its side-effect profile differs meaningfully from dual or single agonists, particularly with respect to heart rate, blood pressure and metabolic parameters. Trial data have reported modest increases in heart rate, which is also observed with other agents in this class.^[17][18] The full safety profile, including any effects on the pancreas, gallbladder, kidneys and cardiovascular system over longer durations, will be characterised more completely as Phase 3 data mature.

Participants in retatrutide trials are excluded if they are pregnant, breastfeeding or planning pregnancy, and appropriate contraception is required as part of trial participation. This reflects standard practice for investigational medicines where reproductive safety data in humans are not yet available.

Anyone participating in a retatrutide clinical trial who experiences a suspected side effect should report it to their trial team in accordance with the study protocol. Suspected adverse reactions to medicines, including those being studied in trials, can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. If a participant experiences a serious or life-threatening symptom, they should call 999 or attend their nearest accident and emergency department immediately.

Frequently Asked Questions